McKesson Corporation Q4 2026 Earnings Recap

MCK Q4 2026 May 8, 2026

Get alerts when MCK reports next quarter

McKesson shares declined modestly by 1.0% following its fiscal Q4 2026 report, reflecting investor caution amid a muted outlook for fiscal 2027 despite stable operational execution and ongoing strategic progress.

Earnings Per Share Beat

$11.69 vs $11.56 est.

+1.1% surprise

Revenue Miss

96295000000 vs 101346200000 est.

-5.0% surprise

Market Reaction

1-Day +0.0%

5-Day +0.15%

See MCK alongside your other holdings

Add to your portfolio — free

Key Takeaways

Adjusted earnings per diluted share grew 18% in fiscal 2026, supported by growth across strategic platforms.
Operating cash flow reached $6.2 billion, surpassing internal plans, with $5.1 billion returned to shareholders.
Continued progress on Medical-Surgical Solutions separation, including transition service agreements and minority investor partnership with Apollo.
Fiscal 2027 EPS guidance range set at $43.80 to $44.60, lacking upward revision and suggesting limited near-term earnings acceleration.
Strategic initiatives such as oncology platform expansion and technology adoption continue, though offset by restrained margin commentary and cautious outlook.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MCK on AllInvestView.

Previous Q3 2026